患有动脉粥样硬化性心血管疾病和2型糖尿病患者使用钠-葡萄糖协同转运蛋白2抑制剂的相关因素：来自退伍军人事务部的见解
Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs.
作者信息
Al Rifai Mahmoud, Mahtta Dhruv, Ramsey David J, Lee Michelle T, Krittanawong Chayakrit, Navaneethan Sankar D, Gregg L Parker, Petersen Laura A, Virani Salim S
机构信息
Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, TX.
Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, TX; Health Policy, Quality & Informatics Program, Michael E. DeBakey VA Medical Center Health Services Research & Development Center for Innovations in Quality, Effectiveness, and Safety, Houston, TX.
出版信息
Am Heart J. 2022 Jun;248:160-162. doi: 10.1016/j.ahj.2021.12.006. Epub 2021 Dec 27.
This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents.
本研究利用退伍军人事务部（VA）的行政和临床数据集，调查了伴有动脉粥样硬化性心血管疾病（ASCVD）和糖尿病的患者使用钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2i）的决定因素。本分析的目的是在当代真实世界患者群体中确定与SGLT-2i相关的障碍和促进因素，以提高这些指南指导药物的使用率。
Zotero 插件